News

Inspire Pharmaceuticals has committed to increasing production of AzaSite in response to the manufacturing supply shortage of erythromycin ophthalmic ointment (0.5%). The FDA has placed erythromycin ophthalmic ointment

Artielle ImmunoTherapeutics (Artielle) has provided the results of a phase 1 safety study of RTL1000, a recombinant T-Cell receptor ligand specific for an immunodominant MOG peptide, in multiple

Study demonstrating, Cardium’s Gene Activated Matrix or GAM technology accelerates periodontal tissue regeneration of oral implant-supporting wounds, was published in the scientific journal, Gene Therapy. According to Cardium,

Antisense Pharma (Antisense) has received orphan drug designation from both the European Medicines Agency (EMEA) and the FDA for its investigational drug, trabedersen, in the treatment of pancreatic

Kenta Biotech (Kenta) has provided positive phase IIa results of its lead drug candidate, panobacumab (KBPA101), showing it is safe and well tolerated in patients with hospital-acquired pneumonia

Rib-X Pharmaceuticals (Rib-X) plans to enter into a Clinical Trials Agreement with the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of

Digestive Care (DCI) has received a complete response letter from the FDA and has moved closer to obtaining approval of its New Drug Application (NDA) for Pancrecarb (pancrelipase).

AVI BioPharma has announced presentation of data regarding the company’s antisense technology for control of the immune response in hemorrhagic virus infections, including Ebola and Marburg virus, at

The FDA has accepted for filing Mylan’s abbreviated new drug application (ANDA) for Glatiramer Acetate Injection (20mg/mL), a generic version of Teva’s Copaxone. The product is indicated for